Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
209 Leser
Artikel bewerten:
(0)

DSM Acquires BioCare Copenhagen to Expand Gut Health Ingredients Portfolio with Probiotics

HEERLEN, Netherlands and COPENHAGEN, December 22, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, announces it has acquired BioCare Copenhagen A/S, based in Copenhagen (Denmark). With the acquisition, DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year. Financial details will not be disclosed at this time.

(Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

BioCare Copenhagen is a privately-held company founded in 2012, focused on probiotics and specialized in microbial actives with proven health benefits, targeting gastrointestinal disorders, metabolic disorders, infections, and immunity. The company offers high-quality white label probiotic supplements and complete product concepts with strong consumer appeal. BioCare Copenhagen has multi-market distribution agreements with a number of leading dietary supplements and pharmaceutical companies and has launched products in over 40 countries worldwide.

DSM already has a strong position in gut health solutions with its Culturelle product range, the number-one-selling probiotic dietary supplement consumer brand globally, as well as with its ingredient brands Oatwell and Tolerase. The company sees further growth potential in gut health ingredients beyond the established indications for digestive health and immune health. Fields increasingly recognized as being impacted by the gut microbiome include the gut-brain axis, metabolic health and heart health. DSM's ambition in addressing the gut microbiome and its portfolio of nutritional ingredients are very synergetic with BioCare Copenhagen's approach and products, and the combination is well-catered to address the existing and emerging gut health areas.

DSM - Bright Science. Brighter Living.'
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com .

BioCare Copenhagen

BioCare Copenhagen is a Danish bioscience company that specializes in microbial actives targeting gastrointestinal disorders, metabolism, infections and immunity. The company's activities are based on research conducted at the Danish hospitals. BioCare Copenhagen was established as a joint venture between Borean Innovation, the Danish Ministry of Science, Technology and Innovation and the management team Soeren B. Thomsen (CEO) and Jesper Gantzel (COO).

DSM Forward-Looking Statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

DSM, Corporate Communications
e-mail: media.contacts@dsm.com
http://www.dsm.com

For more information:
DSM Corporate Communications
Herman Betten
tel. +31(0)45-578-2017
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31(0)-45-578-2864
e-mail dave.huizing@dsm.com

BioCare Copenhagen A/S
Soeren B. Thomsen, CEO
tel.: +45-40325151
e-mail: st@biocarecph.com

BioCare Copenhagen A/S
Jesper N. Gantzel, COO
tel.: +45-20234638
e-mail: jg@biocarecph.com

PDF - http://mma.prnewswire.com/media/622561/DSM_acquires_BioCare_Copenhagen.pdf

PRN NLD


© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.